Seeking Alpha

R. Ennis » Comments » SPPI

  • Ariad Pharmaceuticals: Advancing in Front of Phase 3 Interim Results [View article]
    Oh, I'm fine don't worry about me. I'm sincerely asking you what the near term catalyst is? Is phase III preliminary data still any day?


    On Jul 31 01:02 PM Justin M. Hall wrote:

    > R. Ennis:
    >
    > You should consider listening to the conference call. Merck did
    > not back out on the collaboration with ARIA. You are misrepresenting
    > the facts. One phase 2 trial out of four was discontinued due to
    > the combination of drugs selected for the trial. That's hardly backing
    > out on the deal.
    >
    > As I said earlier this week, ARIA is a speculative play. Maybe this
    > sort of investing is NOT for you. Based on your reaction, you might
    > consider talking with a financial advisor. It appears you may need
    > one.
    >
    > I do wish the best.
    >
    > Justin
    Jul 31 13:41 pm |Rating: 0 0 |Link to Comment
  • Ariad Pharmaceuticals: Advancing in Front of Phase 3 Interim Results [View article]
    What now Justin? Merck backing out of deal, is there still a near term catalyst? I don't see one.

    I'm holding options that expire in Aug. have a feeling they are worthless....


    On Jul 31 03:03 AM Justin M. Hall wrote:

    > Rumi Frost:
    >
    > Thank you for the question.
    >
    > Regarding the ARIA's price, it is very difficult to determine what
    > the price will be following a catalyst.
    >
    > I do share the belief that an interim analysis of Phase 3 data for
    > a potentially [very] effective cancer drug is a significant catalyst,
    > one that investors would likely reward nicely.
    >
    > Because ARIA has a term-friendly collaboration with MRK, most investors
    > could foresee the possibility of an acquisition. It is worth noting
    > that MRK appears on Mike Harvilla's Big Pharma Patent Exposure Index(seekingalpha.com/symbol/c)
    > at biomedreports.com. This means, MRK may need to expand
    > their pipeline as some of their existing drugs are nearing patent
    > expiration. With positive data, deforolimus would certainly make
    > an excellent addition to MRK's cancer drug portfolio.
    >
    > While I did not provide you with a specific price, I hope the response
    > provided is helpful. Thank you again for the question.
    >
    > Good luck!
    >
    > Justin
    Jul 31 11:20 am |Rating: 0 -1 |Link to Comment
More on SPPI by R. Ennis
Comments by Ticker
R. Ennis'
Comments Stats
25 comments
Rating: 33 (76 - 43 )